AM-905 (part of the
AM cannabinoid series) is an
analgesic drug which is a
cannabinoidagonist. It is conformationally restricted by virtue of the double bond on its side chain, leading an increased affinity for and selectivity between
CB1 and
CB2 receptors.[1] It is a potent and reasonably selective agonist for the CB1 cannabinoid
receptor, with a
Ki of 1.2 nM at CB1 and 5.3 nM at CB2.[2]
^Busch-Petersen J, Hill WA, Fan P, Khanolkar A, Xie XQ, Tius MA,
Makriyannis A (September 1996). "Unsaturated side chain beta-11-hydroxyhexahydrocannabinol analogs". Journal of Medicinal Chemistry. 39 (19): 3790–6.
doi:
10.1021/jm950934b.
PMID8809166.
^Papahatjis DP, Kourouli T, Abadji V, Goutopoulos A, Makriyannis A (March 1998). "Pharmacophoric requirements for cannabinoid side chains: multiple bond and C1'-substituted delta 8-tetrahydrocannabinols". Journal of Medicinal Chemistry. 41 (7): 1195–200.
doi:
10.1021/jm970277i.
PMID9544219.
AM-905 (part of the
AM cannabinoid series) is an
analgesic drug which is a
cannabinoidagonist. It is conformationally restricted by virtue of the double bond on its side chain, leading an increased affinity for and selectivity between
CB1 and
CB2 receptors.[1] It is a potent and reasonably selective agonist for the CB1 cannabinoid
receptor, with a
Ki of 1.2 nM at CB1 and 5.3 nM at CB2.[2]
^Busch-Petersen J, Hill WA, Fan P, Khanolkar A, Xie XQ, Tius MA,
Makriyannis A (September 1996). "Unsaturated side chain beta-11-hydroxyhexahydrocannabinol analogs". Journal of Medicinal Chemistry. 39 (19): 3790–6.
doi:
10.1021/jm950934b.
PMID8809166.
^Papahatjis DP, Kourouli T, Abadji V, Goutopoulos A, Makriyannis A (March 1998). "Pharmacophoric requirements for cannabinoid side chains: multiple bond and C1'-substituted delta 8-tetrahydrocannabinols". Journal of Medicinal Chemistry. 41 (7): 1195–200.
doi:
10.1021/jm970277i.
PMID9544219.